Invitae Corporation
NVTA
Pozycja w akcjach
#35785
Invitae Corporation operates as a medical genetics enterprise, striving to... Invitae Corporation operates as a medical genetics enterprise, striving to integrate genetic insights into mainstream medical practice to enhance healthcare outcomes for individuals in the United States, Canada, and internationally. The company provides a comprehensive suite of offerings, including genetic testing for various clinical specializations such as hereditary cancer, cardiovascular health, neurological disorders, pediatric conditions, oncology, metabolic ailments, and rare diseases, alongside digital health tools and health data services. Its clientele spans individual patients, healthcare providers, biopharmaceutical firms, and other collaborators. Established in 2010 as Locus Development, Inc., the company officially became Invitae Corporation in 2012 and is headquartered in San Francisco, California.
Cena akcji
$0.016
Ostatnia synchronizacja: 2024-03-11
Kapitalizacja rynkowa
$3.27M
Zmiana (1 dzień)
-5.33%
Zmiana (1 rok)
5,233.33%
Kraj
US
Handel Invitae Corporation (NVTA)
Kategoria
Healthcare
Zyski dla Invitae Corporation (NVTA)
Zyski w Sep 2023 TTM: $-1.45B
Według najnowszych raportów finansowych Invitae Corporation, obecny zysk firmy wynosi $-1.45B. W roku 2022 firma osiągnęła zysk w wysokości $-3.15B, spadek w porównaniu do zysku z roku 2021, który wynosił $-415.86M. Wyświetlany zysk to zysk przed odsetkami i podatkami, czyli EBIT.
Historia zysków firmy Invitae Corporation od 2016 do 2026
Zyski na koniec każdego roku
| Rok | Zyski | Zmień |
|---|---|---|
| 2026 (TTM) | $-1.45B | -100.00% |
| 2023 | 0.00 | -100.00% |
| 2022 | $-3.15B | 657.75% |
| 2021 | $-415.86M | -41.78% |
| 2020 | $-714.27M | 174.28% |
| 2019 | $-260.42M | 97.05% |
| 2018 | $-132.16M | 5.52% |
| 2017 | $-125.24M | 24.92% |
| 2016 | $-100.26M | 0.00% |
Zyski podobnych firm lub konkurentów
| Firma | Zyski | Różnica w zyskach | Kraj |
|---|---|---|---|
| $7.61B | -623.31% |
US
|
|
| $4.76B | -427.50% |
US
|
|
| $-252.70M | -82.62% |
US
|
|
| - | - |
CN
|
|
| $1.66B | -214.03% |
US
|
